GenFleet Therapeutics closes RMB400m Series B financing

GenFleet Therapeutics has secured nearly 400 million yuan in a Series B round of financing jointly led by CDH Investments, and a healthcare industry fund of government-led Shenzhen Capital Group. South China Venture Capital and Panlin Capital participated in the investment. Existing investors, including Sinopharm Capital, Lake Bleu Capital, and HighLight Capital, also invested in this round.

GenFleet Therapeutics has secured nearly 400 million yuan in a Series B round of financing jointly led by CDH Investments, and a healthcare industry fund of government-led Shenzhen Capital Group. South China Venture Capital and Panlin Capital participated in the investment. Existing investors, including Sinopharm Capital, Lake Bleu Capital, and HighLight Capital, also invested in this round.

The proceeds will be used to finance the overseas registration and clinical trials of the company’s current drug pipeline, the development of its immunological platform, and the construction of an industrial base.

Founded in 2017, GenFleet is a company dedicated to the development of “global new” drugs. The company specializes in developing innovative molecular-level pharmaceuticals and antibody drugs targeting various cancer systems, providing adequate medical solutions to reactivate tumor-specific immune responses and to mobilize the body’s immune system.

The first independent research and development project of the company has been approved to enter the clinic stage by the China Drug Administration in less than two years, and the follow-up product pipeline is also being smoothly promoted and expanded. It is expected that more projects will be clinically registered at home and abroad this year.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/07/genfleet-therapeutics-closes-rmb400m-series-b-financing/.

Leave a Reply

Please Login to Comment